乙基2-羟基-3-(4-甲氧基苯基)丙酸酯 | 33173-51-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 乙基2-羟基-3-(4-甲氧基苯基)丙酸酯
• 英文名称: ethyl (R)-2-hydroxy-3-(4-methoxyphenyl)propanoate
• 英文别名: Ethyl (2R)-2-hydroxy-3-(4-methoxyphenyl)propanoate；(R)-2-Hydroxy-3-(4-methoxy-phenyl)-propionic acid ethyl ester
• CAS: 33173-51-2
• 化学式: C₁₂H₁₆O₄
• 分子量: 224.257
• InChiKey: DRMAXCVIVGDCGQ-LLVKDONJSA-N

物化性质

• 沸点：
  344.1±27.0 °C(Predicted)
• 密度：
  1.137±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  乙酸乙烯酯 、 ethyl 2-hydroxy-3-(4-methoxyphenyl)propanoate 在 Pseudomonas cepacia lipase 作用下， 以 甲基叔丁基醚 为溶剂， 反应 120.0h， 以44%的产率得到ethyl (S)-2-acetoxy-3-(4-methoxyphenyl)propanoate
  参考文献：
  名称：

  Enzyme-mediated synthesis of EEHP and EMHP, useful pharmaceutical intermediates of PPAR agonists

  摘要：

  A new scaleable synthetic route to the title compounds has been developed. The reaction pathway is based on the alpha-chymotrypsin-catalysed hydrolysis of the racemic ethyl 2-ethoxy-3-(p-methoxyphenyl)propanoate or of the racemic ethyl 2-methoxy-3-(p-methoxyphenyl)propanoate to give the corresponding resolved (S)-esters with excellent ee. The acids were easily separated from the (S)-esters by a simple acid-base work-up. The overall yields of 1 and 2 were 16% and 17%, respectively. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2009.10.013

文献信息

• BICYCLIC HETEROCYCLIC DERIVATIVE
  申请人：Nakahira Hiroyuki

  公开号：US20110190278A1

  公开（公告）日：2011-08-04

  The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, being useful as a renin inhibitor. [wherein R 1a is halogen, etc.; R 1m is H, etc.; G 1 is —N(R 1b )—, etc.; G 2 is —CO—, etc.; G 3 is —C(R 1c )(R 1d )—, etc.; G 4 is oxygen, etc.; R 1b is optionally substituted C 1-6 alkyl, etc.; R 1c and R 1d are independently the same or different, H, etc.; R 3 is H, optionally substituted C 1-6 alkyl, etc.; R 3a , R 3b , R 3 c and R 3d are independently the same or different, and a group: -A-B (said A is single bond, etc., and said B is H, etc.), etc.; and n is 1, etc.]

  本发明涉及以下式（I）的化合物或其药学上可接受的盐，其可用作肾素抑制剂。[其中，R1a是卤素等；R1m是H等；G1是—N（R1b）—等；G2是—CO—等；G3是—C（R1c）（R1d）—等；G4是氧等；R1b是可选取代的C1-6烷基等；R1c和R1d独立选择为H等；R3是H、可选取代的C1-6烷基等；R3a、R3b、R3c和R3d独立选择为相同或不同的基团：-A-B（其中A是单键等，B是H等）等；n为1等。]
• Bicyclic heterocyclic derivative
  申请人：Nakahira Hiroyuki

  公开号：US08389511B2

  公开（公告）日：2013-03-05

  The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, being useful as a renin inhibitor. [wherein R1a is halogen, etc.; R1m is H, etc.; G1 is —N(R1b)—, etc.; G2 is —CO—, etc.; G3 is —C(R1c)(R1d)—, etc.; G4 is oxygen, etc.; R1b is optionally substituted C1-6 alkyl, etc.; R1c and R1d are independently the same or different, H, etc.; R3 is H, optionally substituted C1-6 alkyl, etc.; R3a, R3b, R3c and R3d are independently the same or different, and a group: -A-B (said A is single bond, etc., and said B is H, etc.), etc.; and n is 1, etc.]

  本发明涉及以下式（I）的化合物或其药学上可接受的盐，其作为肾素抑制剂有用。[其中R1a为卤素等；R1m为H等；G1为—N（R1b）—等；G2为—CO—等；G3为—C（R1c）（R1d）—等；G4为氧等；R1b为可选取代的C1-6烷基等；R1c和R1d独立且相同或不同，为H等；R3为H、可选取代的C1-6烷基等；R3a、R3b、R3c和R3d独立且相同或不同，为-A-B基团（其中A为单键等，B为H等）等；n为1等。]
• US8389511B2
  申请人：——

  公开号：US8389511B2

  公开（公告）日：2013-03-05
• Enzyme-mediated synthesis of EEHP and EMHP, useful pharmaceutical intermediates of PPAR agonists
  作者：Elisabetta Brenna、Claudio Fuganti、Francesco G. Gatti、Fabio Parmeggiani

  DOI：10.1016/j.tetasy.2009.10.013

  日期：2009.11

  A new scaleable synthetic route to the title compounds has been developed. The reaction pathway is based on the alpha-chymotrypsin-catalysed hydrolysis of the racemic ethyl 2-ethoxy-3-(p-methoxyphenyl)propanoate or of the racemic ethyl 2-methoxy-3-(p-methoxyphenyl)propanoate to give the corresponding resolved (S)-esters with excellent ee. The acids were easily separated from the (S)-esters by a simple acid-base work-up. The overall yields of 1 and 2 were 16% and 17%, respectively. (C) 2009 Elsevier Ltd. All rights reserved.